Prolifagen develops microRNA-based therapies for cardiac regeneration, aiming to prevent heart failure.
Prolifagen has raised $3.0M in total funding. The most recent round was Undisclosed. The last funding was announced in September 2025.
Prolifagen is headquartered in Philadelphia, United States.
Prolifagen develops microRNA-based therapies for cardiac regeneration, aiming to prevent heart failure.
Prolifagen is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prolifagen — Funding & Investors." VCBacked, September 23, 2025, https://www.vcbacked.co/company/prolifagen. Accessed August 14, 2026.
VCBacked. (2025). Prolifagen — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/prolifagen
{{cite web |title=Prolifagen — Funding & Investors |url=https://www.vcbacked.co/company/prolifagen |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated